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Clinically, PET/CT has become an integral part of patient management in oncology, neurology and 
cardiology. By far, oncology aCCoLlnts for most PET/CT applications. 
Dual-modality: PET and CT 
Many might think that PET and Cf were originally incorporated 
together as we know them today only to help nuclear physicians 
in accurately localizing the origin of tracer accumulation, hence 
giving doctors and patients a more defInitive report. In actual 
fact, it was a physicist and an engineer (Townsend and Nutt) 
who implemented dual-modality in order to overcome one of 
the major sources of artefacts in PET: attenuation. This is a 
process by which a beam of radiation is reduced in amplitude 
and intensity when passing through a material, in this case the 
radioactive signal emitted from a point source within the body 
and passing through patient tissues. Attenuation is caused by a 
combination of absorption and scattering processes. The deeper 
within the body the source of radiation is, or the denser the 
tissues, the more the attenuation. To correct for attenuation, 
transmission (as opposed to emission) images derived from an 
external positron-emitting source or an external radioactive 
source, which decays by emission of single events, started being 
used. This required a blank scan and another transmission scan 
of the patient. These methods have been used successfully for 
many years, but were very time-consuming and the radioactive 
source caused noisy transmission images propagated into PET 
images. A breakthrough occurred when high resolution, low 
noise CT transmission maps started being used for attenuation 
comxtioll. D(,~id(,~ tx::Ua qUality aU(,lluatiOll \.:omc\.,tioll of PET 
images and signifIcantly shorter scan times, the superimposition 
of PET and CT improved the interpretation of PET images 
because anatomic and structural characteristics of tissue were 
added to the physiologically mediated distribution of the tracer. 
PET/CT scanners can produce functional PET and anatomical 
CT data in one session, without moving the patient and with 
minimal delay between reconstruction and fusion of the two 
image data setsl . Hitting two hirds with one stone! 
Applications in oncology 
Cancerous cells have high metabolic rates. They use more 
glucose than normal cells. The most widely available PET/CT 
radiopharmaceutical today is an analogue of glucose labelled 
with I sF, fluoro-2-deoxy-D-glucose (lsF-FDG) which has a half-
life of 110 minutes. It was fIrst used in neuro-oncology by a 
team led by Di Chiro in the 1980s2 and then in the detection of 
lung cancer in the 1990s. 'SF_FDG is injected into the bloodstream, 
then transported into the interstitial space from where speciftc 
glucose transporters carry it into cells. Malignant transformation 
is associated with increasing energy demands and upregulation 
of these glucose transporters (especially GLUT-I). Like glucose, 
ISF-FOG is phosphorylated hy hexokinase to ISF-FOG-o-
phosphate. Unlike glucose though, 18F-FDG lacks a hydroxyl 
group on the 2-position and its metabolite 18F-FDG-6-phosphate 
cannot act as a substrate for glycolysis. Therefore the positron-
emitting tracer is 'trapped' in the cell without being further 
Figure 1: Staging and re-staging using 18F_FDG. Metabolic 
PET image superimposed on eT image helps the nuclear 
physician to report with confidence (Images courtesy of 
HSR, Milano) 
metabolized, and dephosphorylation is slow. Another advantage 
of tlus tracor is that IsF FDG is oliminated via tlle kidnoys and 
very little is reabsorbed in the renal tubules, leaving low 18F_ 
FDG levels in blood. 
Clinical scenarios 
18F-FDG PET/CT has become an established technique for 
staging, detection of residual and/or recurrent cancer, signifIcantly 
for planning therapy, and sometimes for diagnosis. Numerous 
studies demonstrate how PET/CT is essential in staging and 
restaging of most cancers including breast, cervical, colorectal, 
gastric, oesophageal, head and neck, lymphoma, lung, ovarian, 
uterine, thyroid, testicular, pancreatic, gall bladder and bile duct, 
renal, bladder, melanoma and sarcoma. 
To illustrate further the clinical utility of 18FDG PET/CT and 
to highlight tlle fact that many times this imaging technique is 
indispensable, some representative and common clinical situations 
are illustrated below: 
A. In patients with 'radiologically indeterminate' pulmonary 
nodules, doctors may opt for a risky 'wait-and-see' or an 
invasive biopsy which could be marred by complications or 
false negatives, especially when nodules are in hard-to-reach 
locations and in cases of inadequate tissue collection. PET/Cf 
has a very high negative predicative value. When negative, 
a biopsy can be avoided. 
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Figure 2: Two patients presenting with a pulmonary nodule. In one patient (above left), the nodule showed no tracer 
uptake, and a biopsy was avoided. In the other patient (above right), the nodule showed avid tracer uptake. Moreover, 
whole-body PET/eT allowed immediate staging of the patient with the very suspicious lung lesion. Metabolic characterisation 
of pulmonary nodules is also very important when these are located in areas which are impossible to reach by a biopsy 
needle (Images courtesy of HSR, Milan) 
B. PET/CT is more sensitive than CT in pre-operative 
staging of most carcinomas; for example, many studies 
show that in oesophageal carcinomas, a significant 
number of patients deemed operable by CT may have 
unsuspected metastases which can be identified by 
PET/CT, hence drastically altering management3• 
C. A drawback of 'conventional' imaging techniques is their 
reliance on size criteria to define disease such as in the 
case of lymph nodes, with the consequent failure to 
detect disease in small lymph nodes and to exclude 
disease in larger lymph nodes. 18F-FDG often permits 
distinction of suspicious lymph nodes as malignant or 
disease-free, also avoiding unnecessary procedures such 
as biopsies or mediastinoscopies. PET/CT staging and 
restaging (assessment of therapy) of Hodgkin's and non-
IIodgkin's lymphoma is superior to stand alone CT and 
gallium scintigraphy4. 
D. In some carcinomas it is possible to follow-up using 
tumour markers (e.g. colorectal, ovarian, breast and 
pancreatic carcinomas). PET/CT is an asset in patients 
presenting with rising tumour markers during follow-
up and with negative conventional morphological 
imaging. PET/CT allows the addition of early metabolic 
change data to the morphological images, potentially 
determining the cause of tumour marker rise. FDG-PET 
is also a valuable diagnostic tool in patients with cancer 
of unknown primary (which conventional imaging 
modalities fail to detect). These patients would initially 
present with metastasic lesions (e.g. bone, lymph nodes, 
lung)5. 
E. Increased tumour uptake is a function of proliferative 
activity and is also related to viable tumour cell number. 
Hence, if 18F-FDG is related to tumour cell viability, 
then reduction in uptake (with effective chemotherapy) 
should reflect increased tumour cell killing rate. Clinical 
trials have demonstrated uptake of 18F-FDG as an early 
and sensitive pharmacodynamic marker of the anti-
tumoral effect of chemotherapy, even as early as the first 
cycle of chemotherapy6. The oncologist can consider 
changing a chemotherapy regime early on, avoiding 
extra costs in suboptimal therapies and saving the patient 
from side-effects. 
F. When a patient presents with a tumour (as in lung 
carcinoma) with surrounding oedema, PET/CT permits 
the evaluation of the exact extent of the lesion, thus 
allowing better radiotherapy planning. Nowadays, 
PET images are used directly for radiotherapy 
purposes. Post-radiotherapy PET/CT helps determine 
whether any residual viable tumour is still present. 
This is difficult to distinguish on CT because both 
scar tissue (radiotherapy changes) and disease can 
alter anatomy.8J 
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